EGFR and non-small cell lung carcinoma: For instance, durable responses in T790M EGFR-mutant NSCLC patients with acquired resistance to other TKIs were induced by osimertinib (Tagrisso) that was approved recently by both FDA and European Medicines Agency (EMA) for T790M mutation-positive NSCLC60,61.